FDA Approves Updated Indication Statement for Rinvoq (upadacitinib) for the Treatment of Inflammatory Bowel Disease

Oct 16, 2025 - 18:00
 0  1
NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for Rinvoq (upadacitinib)...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0